Home
MLTX
MLTX News

Latest MoonLake Immunotherapeutics (MLTX) News on October 8, 2025

MoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal Scrutiny

Simply Wall St.

4 days ago

MoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal Scrutiny

MT Newswires

6 days ago

HC Wainwright Downgrades MoonLake Immunotherapeutics to Neutral From Buy

MT Newswires

7 days ago

Goldman Sachs Downgrades MoonLake Immunotherapeutics to Neutral From Buy, Cuts Price Target to $7 From $82

Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX)

Insider Monkey

a month ago

Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX)

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

Zacks

4 months ago

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

MT Newswires

4 months ago

Update: Market Chatter: Merck Held Talks to Buy MoonLake for Over $3 Billion; MoonLake Shares Rise

Constellation and Meta, Merck, Snowflake: Trending Tickers

Yahoo Finance Video

4 months ago

Constellation and Meta, Merck, Snowflake: Trending Tickers

MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid

Investor's Business Daily

4 months ago

MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid

MT Newswires

4 months ago

Market Chatter: Merck Held Talks to Buy MoonLake for Over $3 Billion; MoonLake Shares Rise Pre-Bell

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

Benzinga

4 months ago

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Reuters

4 months ago

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Newsfile

4 months ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

Newsfile

4 months ago

Carbone Restaurant Group is a GOLD Sponsor at the Centurion One Capital 6th Annual LA Summit

Energy Global

4 months ago

European Energy completes sale of Polish wind portfolio to Enea Group

Newsfile

4 months ago

Sienna Resources Inc. Announces Private Placement

First Foundation Bank review (2025): Personal and business banking with competitive online rates

Yahoo Personal Finance

4 months ago

First Foundation Bank review (2025): Personal and business banking with competitive online rates

Investing.com

4 months ago

Airbnb shares dip as Truist cuts stock to Sell on weak summer trends, valuation

Report: Slower economy doesn't dim downtown Austin's dynamism

Austin American-Statesman

4 months ago

Report: Slower economy doesn't dim downtown Austin's dynamism

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance

GuruFocus.com

4 months ago

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT

Insider Monkey

4 months ago

H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT

MT Newswires

5 months ago

Wolfe Research Upgrades MoonLake Immunotherapeutics to Outperform From Peer Perform

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

Zacks

5 months ago

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

MT Newswires

5 months ago

Wedbush Adjusts Price Target on MoonLake Immunotherapeutics to $80 From $78, Maintains Outperform Rating

MT Newswires

5 months ago

MoonLake Immunotherapeutics Q1 Loss Widens

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

GlobeNewswire

5 months ago

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

GlobeNewswire

5 months ago

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Insider Monkey

5 months ago

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

MT Newswires

6 months ago

MoonLake Obtains $500 Million Facility From Hercules Capital

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

GlobeNewswire

6 months ago

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MT Newswires

7 months ago

Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target

MT Newswires

7 months ago

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target

MT Newswires

7 months ago

MoonLake Immunotherapeutics Q4 Loss Widens

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire

7 months ago

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?

Insider Monkey

7 months ago

Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey

7 months ago

MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts

MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now

Insider Monkey

8 months ago

MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now

We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely

Simply Wall St.

8 months ago

We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely

MT Newswires

9 months ago

Goldman Sachs Upgrades MoonLake Immunotherapeutics to Buy From Neutral, Adjusts Price Target to $82 From $62

MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG

TipRanks

9 months ago

MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG

MT Newswires

9 months ago

BTIG Adjusts MoonLake Immunotherapeutics' Price Target to $81 From $71, Keeps Buy Rating

MT Newswires

9 months ago

MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says

MT Newswires

9 months ago

MoonLake Immunotherapeutics Starts Three New Clinical Trials Evaluating Sonelokimab in Inflammatory Diseases

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

GlobeNewswire

9 months ago

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?

Simply Wall St.

9 months ago

Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

GlobeNewswire

a year ago

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MT Newswires

a year ago

MoonLake Immunotherapeutics' Q3 Net Loss Widens

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/09/2024

GuruFocus.com

a year ago

Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics

MT Newswires

a year ago

Moonlake Immunotherapeutics Insider Sold Shares Worth $9,186,120, According to a Recent SEC Filing

Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?

Insider Monkey

a year ago

Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?

MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock

Insider Monkey

a year ago

MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

GlobeNewswire

a year ago

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months

Insider Monkey

a year ago

MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months

MT Newswires

a year ago

MoonLake Immunotherapeutics Shares Fall After Wolfe Research Downgrade

MT Newswires

a year ago

Wolfe Research Downgrades MoonLake Immunotherapeutics to Peer Perform From Outperform

We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow

Simply Wall St.

a year ago

We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow

MT Newswires

a year ago

MoonLake Immunotherapeutics Shares Slightly Up Despite Wider Q2 Loss

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MT Newswires

a year ago

Oppenheimer Initiates MoonLake Immunotherapeutics at Outperform With $104 Price Target

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

GlobeNewswire

a year ago

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

Motley Fool

a year ago

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

CNW Group

a year ago

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

Investor's Business Daily

a year ago

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

EPCOR and HAWSCo Enter Ownership Transfer Agreement

CNW Group

a year ago

EPCOR and HAWSCo Enter Ownership Transfer Agreement

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

GlobeNewswire

a year ago

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

Southwest Airlines stock pops on report of Elliott's $2B stake

Yahoo Finance Video

a year ago

Southwest Airlines stock pops on report of Elliott's $2B stake

Business Wire

a year ago

Form 8.3 - Virgin Money UK plc

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

GlobeNewswire

a year ago

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

GuruFocus.com

a year ago

MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes

MT Newswires

a year ago

MoonLake Immunotherapeutics Q1 Net Loss Widens

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

a year ago

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Business Wire

a year ago

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

Simply Wall St.

2 years ago

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

Investor's Business Daily

2 years ago

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

GlobeNewswire

2 years ago

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

GlobeNewswire

2 years ago

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)

GuruFocus.com

2 years ago

Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

GlobeNewswire

2 years ago

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

GlobeNewswire

2 years ago

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics

GuruFocus.com

2 years ago

Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics

Beazer Homes (BZH) Q1 Earnings & Revenues Miss, Orders Up

Zacks

2 years ago

Beazer Homes (BZH) Q1 Earnings & Revenues Miss, Orders Up

Zurn Elkay Water Solutions Declares Quarterly Cash Dividend

Business Wire

2 years ago

Zurn Elkay Water Solutions Declares Quarterly Cash Dividend

Why Fast-paced Mover Celestica (CLS) Is a Great Choice for Value Investors

Zacks

2 years ago

Why Fast-paced Mover Celestica (CLS) Is a Great Choice for Value Investors

Noble Corporation plc announces changes to its share capital for the month of January 2024

PR Newswire

2 years ago

Noble Corporation plc announces changes to its share capital for the month of January 2024

Rush Enterprises, Inc. Conference Call Advisory for Fourth Quarter and Year-End 2023 Earnings Results

GlobeNewswire

2 years ago

Rush Enterprises, Inc. Conference Call Advisory for Fourth Quarter and Year-End 2023 Earnings Results

Argus Research

2 years ago

Daily – Vickers Top Buyers & Sellers for 01/31/2024

Director John Schultz Acquires 8,559 Shares of Columbia Banking System Inc

GuruFocus.com

2 years ago

Director John Schultz Acquires 8,559 Shares of Columbia Banking System Inc

Is Janus Henderson Enterprise I (JMGRX) a Strong Mutual Fund Pick Right Now?

Zacks

2 years ago

Is Janus Henderson Enterprise I (JMGRX) a Strong Mutual Fund Pick Right Now?

VNT vs. VLTO: Which Stock Should Value Investors Buy Now?

Zacks

2 years ago

VNT vs. VLTO: Which Stock Should Value Investors Buy Now?

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

Motley Fool

2 years ago

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

GlobeNewswire

2 years ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

3 Asset Management Stocks Set to Pull Off Earnings Beat in Q4

Zacks

2 years ago

3 Asset Management Stocks Set to Pull Off Earnings Beat in Q4

Novo Nordisk Puts Pharma Peers in the Shade as Key Earnings Reports Awaited

Bloomberg

2 years ago

Novo Nordisk Puts Pharma Peers in the Shade as Key Earnings Reports Awaited

MAG Silver (MAG) Reports Solid Production at Juanicipio

Zacks

2 years ago

MAG Silver (MAG) Reports Solid Production at Juanicipio

19 Best Reusable Water Bottles on Amazon Under $50

Insider Monkey

2 years ago

19 Best Reusable Water Bottles on Amazon Under $50

Are You Looking for a High-Growth Dividend Stock?

Zacks

2 years ago

Are You Looking for a High-Growth Dividend Stock?

Business Wire

2 years ago

Webster Financial Corporation Declares Common and Preferred Dividends

Here's Why Transocean (RIG) Fell More Than Broader Market

Zacks

2 years ago

Here's Why Transocean (RIG) Fell More Than Broader Market

Share on Social Networks: